C.M. Pirie
Pfizer (United States)(US)
Publications by Year
Research Areas
Bone health and osteoporosis research, Estrogen and related hormone effects, Bone Metabolism and Diseases, Growth Hormone and Insulin-like Growth Factors, Menopause: Health Impacts and Treatments
Most-Cited Works
- → FDA guidelines and animal models for osteoporosis(1995)523 cited
- → Effects of CP-336,156, a New, Nonsteroidal Estrogen Agonist/Antagonist, on Bone, Serum Cholesterol, Uterus, and Body Composition in Rat Models(1998)157 cited
- → Discovery and Preclinical Pharmacology of a Novel, Potent, Nonsteroidal Estrogen Receptor Agonist/Antagonist, CP-336156, a Diaryltetrahydronaphthalene(1998)131 cited
- → Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model(1997)123 cited
- → Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.(1995)114 cited
- → Prostaglandin E2 increases bone strength in intact rats and in ovariectomized rats with established osteopenia(1998)61 cited
- → Effects of Growth Hormone Supplementation on Left Ventricular Morphology and Myocyte Function With the Development of Congestive Heart Failure(1999)55 cited
- → Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs)(2003)47 cited
- → Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats(1995)42 cited
- → Treatment With a Growth Hormone Secretagogue in a Model of Developing Heart Failure(2001)41 cited